Shares of Helix BioPharma Corp. (TSE:HBP - Get Free Report) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of C$0.92 and traded as high as C$0.95. Helix BioPharma shares last traded at C$0.95, with a volume of 2,500 shares traded.
Helix BioPharma Stock Performance
The business's 50 day moving average is C$0.91 and its 200 day moving average is C$0.97. The company has a market capitalization of C$42.42 million, a price-to-earnings ratio of -0.84 and a beta of -0.84.
Helix BioPharma Company Profile
(
Get Free Report)
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
Featured Stories
Before you consider Helix BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Helix BioPharma wasn't on the list.
While Helix BioPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 best stocks to own in Spring 2025, carefully selected for their growth potential amid market volatility. This exclusive report highlights top companies poised to thrive in uncertain economic conditions—download now to gain an investing edge.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
